Physician profile
Thomas J Boland
NPI 1679531867
$3,467.72
in general payments reported to CMS, 2019-2025
12 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Oral and Maxillofacial Surgery provider received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $202 · 2021: $1,498 · 2022: $397 · 2023: $204 · 2024: $670 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salvin Dental Specialties, INC. | $1,423.02 | 2020-2021 | |
| Straumann USA LLC | $823.49 | 2021-2025 | |
| Depuy Synthes Sales INC. | $308.98 | 2022-2025 | Matrixorthognathic |
| Kls-Martin L.P. | $157.74 | 2022-2025 | |
| Biohorizons Implant Systems INC. | $154.66 | 2019-2024 | Biohorizons |
| Nobel Biocare USA | $135.04 | 2019-2022 | |
| Zimmer Biomet Holdings, INC. | $126.19 | 2020-2021 | |
| Stryker Corporation | $119.06 | 2022-2025 | Medpor Titan, Na, Stryker Varispeed |
| Geistlich Pharma, North America, INC. | $92.27 | 2021-2025 | Bio-Materials, Biomaterials |
| Zimvie INC. | $75.96 | 2022-2023 | |
| Mvp Orthopedics INC | $32.09 | 2022 | |
| Orapharma, A Division of Bausch Health US, LLC | $19.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Boland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.